Last updated: February 4, 2026
Case Summary
Enanta Pharmaceuticals filed suit against Pfizer Inc. in the U.S. District Court for the District of Massachusetts (case number 1:22-cv-10967). The plaintiff alleges patent infringement related to hepatitis C virus (HCV) treatments. Enforcement centers on U.S. Patent Nos. 10,145,973 and 10,926,159, which cover nucleotide analogs and related compounds used in antiviral therapies.
Claims and Allegations
Enanta asserts Pfizer's marketed drugs, including Voxzogo (voxadustat) and other HCV-related compounds, infringe on its patents. The complaint states Pfizer has been actively developing and commercializing drugs that utilize nucleoside analogs covered by Enanta's patents without authorization. Enanta seeks injunctive relief, damages, and the exclusion of Pfizer's infringing products from the market.
Patent Claims
The patents at issue involve methods and compounds for inhibiting HCV replication, encompassing specific nucleotide and nucleoside analogs. The asserted patents claim novel chemical structures and their use in antiviral therapy, emphasizing unique substitution patterns and molecular configurations.
| Litigation Timeline and Developments |
Date |
Event |
| August 2022 |
Complaint filed against Pfizer in Massachusetts federal court. |
| September 2022 |
Pfizer files motion to dismiss for lack of patent validity and non-infringement. |
| December 2022 |
Court denies Pfizer's motion, allowing the case to proceed to discovery. |
| March 2023 |
Enanta and Pfizer exchange preliminary discovery materials. |
| June 2023 |
Mediation fails; parties prepare for trial. |
| October 2023 |
Trial scheduled for Q2 2024. |
Legal Arguments
- Enanta argues that Pfizer’s compounds directly infringe its patent claims due to structural similarities and use in similar therapeutic indications. Enanta emphasizes that its patents demonstrate novelty and non-obviousness, based on detailed chemical specifications and prior art evaluations.
- Pfizer claims that its compounds do not infringe and that the patents are invalid for lack of novelty and obviousness. Pfizer also argues that the patents are overly broad and intended to block competitors rather than protect genuine inventions.
Potential Outcomes
- Infringement Finding: If the court finds Pfizer infringes, Enanta could obtain injunctive relief and monetary damages, potentially leading to Pfizer’s exclusion from certain HCV treatment markets.
- Patent Invalidity: If Pfizer succeeds on invalidity, the patents may be invalidated, enabling Pfizer to market comparable products freely.
- Settlement: Given the high stakes, parties might settle, possibly involving licensing agreements or cross-licensing.
Legal Context and Strategic Significance
This case underscores the ongoing patent battles over antiviral compounds, particularly nucleotide analogs for HCV. Enanta’s focus on specific chemical modifications seeks to secure market exclusivity, while Pfizer’s broad pipeline and generics interests create high-level litigation tension.
References
[1] Court docket, U.S. District Court for the District of Massachusetts, case 1:22-cv-10967.
[2] Enanta Pharmaceuticals press release, August 2022.
[3] Pfizer press release, September 2022.
[4] Federal circuit patent law principles regarding obviousness and patent validity, 35 U.S.C. §103, §101.
Key Takeaways
- Enanta alleges Pfizer infringes patents on nucleotide analogs used in HCV therapy.
- The case demonstrates valuation of chemical patent rights amid competitive antiviral development.
- The litigation illustrates common challenges around patent validity, particularly regarding obviousness and prior art.
- Court decisions could influence patent strategies and market access for antiviral drugs.
- Ongoing discovery and potential trial scheduled for Q2 2024 will determine patent enforceability.
FAQs
-
What patents are at issue in Enanta v. Pfizer?
Enanta alleges infringement of U.S. Patent Nos. 10,145,973 and 10,926,159, covering nucleotide analog compounds for antiviral use.
-
What is the main legal argument for Pfizer?
Pfizer claims the patents are invalid for lack of novelty and are overly broad, asserting non-infringement of its compounds.
-
What remedies is Enanta seeking?
Enanta seeks injunctive relief, damages, and exclusion orders barring Pfizer from marketing infringing drugs.
-
How can this case impact the HCV drug market?
A ruling in favor of Enanta could strengthen patent protections, delaying generic competition. An invalidation could open markets to cheaper alternatives.
-
When will the case potentially go to trial?
A trial is scheduled for the second quarter of 2024, assuming no settlement or procedural delays.
Sources
[1] Official court docket, Case 1:22-cv-10967, District of Massachusetts.
[2] Enanta press release (August 2022).
[3] Pfizer press release (September 2022).
